The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 8 of 13
Back to Result List

Short and long-term effectiveness of ustekinumab in patients with Crohn’s disease: Real-world data from a German IBD cohort

  • Background and Aims: The IL-12/23 inhibitor ustekinumab (UST) opened up new treatment options for patients with Crohn’s disease (CD). Due to the recent approval, real-world German data on long-term efficacy and safety are lacking. This study aimed to assess the clinical course of CD patients under UST therapy and to identify potential predictive markers. Methods: Patients with CD receiving UST treatment in three hospitals and two outpatient centers were included and retrospectively analyzed. Rates for short- and long-term remission and response were analyzed with the help of clinical (Harvey–Bradshaw Index (HBI)) and biochemical (C-reactive protein (CRP), Fecal calprotectin (fCal)) parameters for disease activity. Results: Data from 180 patients were evaluated. One-hundred-and-six patients had a follow-up of at least eight weeks and were included. 96.2% of the patients were pre-exposed to anti- TNFα agents and 34.4% to both anti-TNFα and anti-integrin antibodies. The median follow-up was 49.1 weeks (95% CI 42.03-56.25). At week 8, 51 patients (54.8%) showed response to UST, and 24 (24.7%) were in remission. At week 48, 48 (51.6%) responded to UST, and 25 patients (26.9%) were in remission. Steroid-free response and remission at week eight was achieved by 30.1% and 19.3% of patients, respectively. At week 48, 37.6% showed steroid-free response to UST, and 20.4% of the initial patient population was in steroid-free remission. Conclusion: Our study confirms short- and long-term UST effectiveness and tolerability in a cohort of multi-treatment-exposed patients.

Download full text files

Export metadata

Metadaten
Author:Alica KubeschORCiDGND, Laurenz Rueter, Karima Farrag, Thomas Krause, Klaus Stienecker, Johannes HausmannORCiDGND, Natalie FilmannORCiDGND, Axel Uwe Dignass, Jürgen SteinORCiDGND, Irina Ursula BlumensteinORCiDGND
URN:urn:nbn:de:hebis:30:3-527476
DOI:https://doi.org/10.3390/jcm8122140
ISSN:2077-0383
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/31817134
Parent Title (English):Journal of Clinical Medicine
Publisher:MDPI
Place of publication:Basel
Document Type:Article
Language:English
Year of Completion:2019
Date of first Publication:2019/12/04
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2020/02/12
Tag:Crohn’s disease; IBD; biologics; efficacy; real-world data; ustekinumab
Volume:8
Issue:12, Art. 2140
Page Number:11
First Page:1
Last Page:11
Note:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
HeBIS-PPN:460971786
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Open-Access-Publikationsfonds:Medizin
Licence (German):License LogoCreative Commons - Namensnennung 4.0